Neoatherosclerosis: Overview of histopathologic findings and implications for intravascular imaging assessment

European Heart Journal

Volumn 36, Issue 32, 2015, Pages 2147-2159

  Otsuka, Fumiyuki ^a   Byrne, Robert A ^b   Yahagi, Kazuyuki ^a   Mori, Hiroyoshi ^a   Ladich, Elena ^a   Fowler, David R ^c   Kutys, Robert ^a   Xhepa, Erion ^b   Kastrati, Adnan ^b   Virmani, Renu ^a   Joner, Michael ^a  

^a CVPATH INSTITUTE   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c OFFICE OF THE CHIEF MEDICAL EXAMINER   (United States)

Author keywords

Coronary disease; Imaging; Neoatherosclerosis; Pathology; Restenosis; Stents; Thrombosis

Indexed keywords

AUTOPSY; BRAIN ATHEROSCLEROSIS; CELL INFILTRATION; CELL JUNCTION; CELL PROLIFERATION; DEVICE FAILURE; DISEASE COURSE; HUMAN; IN-STENT RESTENOSIS; INTRAVASCULAR ULTRASOUND; MORPHOLOGICAL TRAIT; NEAR INFRARED SPECTROSCOPY; NEOINTIMA; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER; ATHEROSCLEROTIC PLAQUE; CARDIAC IMAGING; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; GRAFT OCCLUSION; PATHOLOGY; PROCEDURES; PROSTHESIS FAILURE; RUPTURE;

AUTOPSY; CARDIAC IMAGING TECHNIQUES; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; GRAFT OCCLUSION, VASCULAR; HUMANS; PLAQUE, ATHEROSCLEROTIC; PROSTHESIS FAILURE; RUPTURE, SPONTANEOUS; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84940208241     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv205     Document Type: Review

References (55)

1. Mieres JH. Review of the American Heart Association's guidelines for cardiovascular disease prevention in women. Heart 2006;92 (Suppl. 3):iii10-13.
2. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER III, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Heart disease and stroke statistics - 2014 update: a report from the American Heart Association. Circulation 2014;129:e28-e292.
3. Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe J, Overlie P, Donohue B, Chelliah N, Timmis GC, Vlietstra RE, Strzelecki M, Puchrowicz-Ochocki S, O'Neill WW; the Primary Angioplasty in Myocardial Infarction Study Group. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1993;328:673-679.
4. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, Gibson CM, Braunwald E. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-1887.
5. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
6. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202.
7. Kimura T, Morimoto T, Nakagawa Y, Kawai K, Miyazaki S, Muramatsu T, Shiode N, Namura M, Sone T, Oshima S, Nishikawa H, Hiasa Y, Hayashi Y, Nobuyoshi M, Mitudo K. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry. Circulation 2012;125:584-591.
8. Tada T, Byrne RA, Simunovic I, King LA, Cassese S, Joner M, Fusaro M, Schneider S, Schulz S, Ibrahim T, Ott I, Massberg S, Laugwitz KL, Kastrati A. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. JACC Cardiovasc Interv 2013;6:1267-1274.
9. Raber L, Magro M, Stefanini GG, Kalesan B, van Domburg RT, Onuma Y, Wenaweser P, Daemen J, Meier B, Juni P, Serruys PW, Windecker S. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation 2012;125:1110-1121.
10. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Juni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369:667-678.
11. Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Juni P, Vaina S, Hellige G, Tsuchida K, Morger C, Boersma E, Kukreja N, Meier B, Serruys PW, Windecker S. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol 2008;52:1134-1140.
12. Cassese S, Byrne RA, Tada T, Pinieck S, Joner M, Ibrahim T, King LA, Fusaro M, Laugwitz KL, Kastrati A. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart 2014;100:153-159.
13. Natsuaki M, Morimoto T, Furukawa Y, Nakagawa Y, Kadota K, Yamaji K, Ando K, Shizuta S, Shiomi H, Tada T, Tazaki J, Kato Y, Hayano M, Abe M, Tamura T, Shirotani M, Miki S, Matsuda M, Takahashi M, Ishii K, Tanaka M, Aoyama T, Doi O, Hattori R, Kato M, Suwa S, Takizawa A, Takatsu Y, Shinoda E, Eizawa H, Takeda T, Lee JD, Inoko M, Ogawa H, Hamasaki S, Horie M, Nohara R, Kambara H, Fujiwara H, Mitsudo K, Nobuyoshi M, Kita T, Kimura T. Late adverse events after implantation of sirolimus-eluting stent and bare-metal stent: long-term (5-7 years) follow-up of the coronary revascularization demonstrating outcome study-kyoto registry cohort-2. Circ Cardiovasc Interv 2014;7:168-179.
14. Brener SJ, Kereiakes DJ, Simonton CA, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Smith RS Jr, Ying SW, Cutlip DE, Stone GW. Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the treatment of subjects with de novo native coronary artery lesions trial. Am Heart J 2013;166:1035-1042.
15. Lee JM, Park KW, Han JK, Yang HM, Kang HJ, Koo BK, Bae JW, Woo SI, Park JS, Jin DK, Jeon DW, Oh SK, Kim DI, Hyon MS, Jeon HK, Lim DS, Kim MG, Rha SW, Her SH, Hwang JY, Kim S, Choi YJ, Kang JH, Moon KW, Jang Y, Kim HS. Three-year patient-related and stent-related outcomes of secondgeneration everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice (from the Multicenter Prospective EXCELLENT and RESOLUTE-Korea Registries). Am J Cardiol 2014;114:1329-1338.
16. Camenzind E, Wijns W, Mauri L, Kurowski V, Parikh K, Gao R, Bode C, Greenwood JP, Boersma E, Vranckx P, McFadden E, Serruys PW, O'Neil WW, Jorissen B, Van Leeuwen F, Steg PG. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet 2012;380:1396-1405.
17. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007;115:2435-2441.
18. Nakazawa G, Finn AV, Vorpahl M, Ladich ER, Kolodgie FD, Virmani R. Coronary responses and differential mechanisms of late stent thrombosis attributed to firstgeneration sirolimus- and paclitaxel-eluting stents. J Am Coll Cardiol 2011;57:390-398.
19. Nakazawa G, Finn AV, Vorpahl M, Ladich E, Kutys R, Balazs I, Kolodgie FD, Virmani R. Incidence and predictors of drug-eluting stent fracture in human coronary artery a pathologic analysis. J Am Coll Cardiol 2009;54:1924-1931.
20. Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yazdani SK, Ladich E, Kolodgie FD, Finn AV, Virmani R. The pathology of neoatherosclerosis in human coronary implants: bare-metal and drug-eluting stents. J Am Coll Cardiol 2011;57:1314-1322.
21. Nakazawa G, Vorpahl M, Finn AV, Narula J, Virmani R. One step forward and two steps back with drug-eluting-stents: from preventing restenosis to causing late thrombosis and nouveau atherosclerosis. JACC Cardiovasc Imaging 2009;2:625-628.
22. Otsuka F, Vorpahl M, Nakano M, Foerst J, Newell JB, Sakakura K, Kutys R, Ladich E, Finn AV, Kolodgie FD, Virmani R. Pathology of second-generation everolimuseluting stents versus first-generation sirolimus- and Paclitaxel-eluting stents in humans. Circulation 2014;129:211-223.
23. Otsuka F, Sakakura K, Yahagi K, Joner M, Virmani R. Has our understanding of calcification in human coronary atherosclerosis progressed? Arterioscler Thromb Vasc Biol 2014;34:724-736.
24. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS, Skorija K, Cheng Q, Xu X, Gold HK, Kolodgie FD, Virmani R. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008;52:333-342.
25. Nakazawa G, Nakano M, Otsuka F, Wilcox JN, Melder R, Pruitt S, Kolodgie FD, Virmani R. Evaluation of polymer-based comparator drug-eluting stents using a rabbit model of iliac artery atherosclerosis. Circ Cardiovasc Interv 2011;4:38-46.
26. Otsuka F, Finn AV, Yazdani SK, Nakano M, Kolodgie FD, Virmani R. The importance of the endothelium in atherothrombosis and coronary stenting. Nat Rev Cardiol 2012;9:439-453.
27. Guagliumi G, Farb A, Musumeci G, Valsecchi O, Tespili M, Motta T, Virmani R. Images in cardiovascular medicine. Sirolimus-eluting stent implanted in human coronary artery for 16 months: pathological findings. Circulation 2003;107:1340-1341.
28. Jimenez JM, Davies PF. Hemodynamically driven stent strut design. Ann Biomed Eng 2009;37:1483-1494.
29. Davies PF. Hemodynamic shear stress and the endothelium in cardiovascular pathophysiology. Nat Clin Pract Cardiovasc Med 2009;6:16-26.
30. Nakazawa G, Ladich E, Finn AV, Virmani R. Pathophysiology of vascular healing and stent mediated arterial injury. EuroIntervention 2008;4 Suppl C:C7-10.
31. Nakano M, Otsuka F, Yahagi K, Sakakura K, Kutys R, Ladich ER, Finn AV, Kolodgie FD, Virmani R. Human autopsy study of drug-eluting stents restenosis: histomorphological predictors and neointimal characteristics. Eur Heart J 2013;34:3304-3313.
32. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995;15:551-561.
33. Tabas I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol 2005;25:2255-2264.
34. Tulenko TN, Chen M, Mason PE, Mason RP. Physical effects of cholesterol on arterial smooth muscle membranes: evidence of immiscible cholesterol domains and alterations in bilayer width during atherogenesis. J Lipid Res 1998;39:947-956.
35. Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, Gold HK, Burke AP, Kolodgie FD, Virmani R. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation 2008;118:1138-1145.
36. Wakabayashi K, Mintz GS, Weissman NJ, Stone GW, Ellis SG, Grube E, Ormiston JA, Turco MA, Pakala R, Xue Z, Desale S, Laynez-Carnicero A, Romaguera R, Sardi G, Pichard AD, Waksman R. Impact of drug-eluting stents on distal vessels. Circ Cardiovasc Interv 2012;5:211-219.
37. Wakabayashi K, Waksman R, Weissman NJ. Edge effect from drug-eluting stents as assessed with serial intravascular ultrasound: a systematic review. Circ Cardiovasc Interv 2012;5:305-311.
38. Thorp E, Tabas I. Mechanisms and consequences of efferocytosis in advanced atherosclerosis. J Leukoc Biol 2009;86:1089-1095.
39. Otsuka F, Sakakura K, Yahagi K, Sanchez OD, Kutys B, Ladich E, Fowler DR, Kolodgie FD, Davis HR, Joner M, Virmani R. Contribution of in-stent neoatherosclerosis to late stent failure following bare metal and 1st- and 2nd-generation drug-eluting stent placement: an autopsy study. J Am Coll Cardiol 2014; 64(11 Suppl.):B190-B191.
40. Yamaji K, Kimura T, Morimoto T, Nakagawa Y, Inoue K, Soga Y, Arita T, Shirai S, Ando K, Kondo K, Sakai K, Goya M, Iwabuchi M, Yokoi H, Nosaka H, Nobuyoshi M. Very long-term (15 to 20 years) clinical and angiographic outcome after coronary bare metal stent implantation. Circ Cardiovasc Interv 2010;3:468-475.
41. Doyle B, Rihal CS, O'Sullivan CJ, Lennon RJ, Wiste HJ, Bell M, Bresnahan J, Holmes DR Jr. Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation 2007;116:2391-2398.
42. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987;316:1371-1375.
43. Burke AP, Kolodgie FD, Farb A, Weber DK, Malcom GT, Smialek J, Virmani R. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation 2001;103:934-940.
44. Yokoyama S, Takano M, Yamamoto M, Inami S, Sakai S, Okamatsu K, Okuni S, Seimiya K, Murakami D, Ohba T, Uemura R, Seino Y, Hata N, Mizuno K. Extended follow-up by serial angioscopic observation for bare-metal stents in native coronary arteries: from healing response to atherosclerotic transformation of neointima. Circ Cardiovasc Interv 2009;2:205-212.
45. Higo T, Ueda Y, Oyabu J, Okada K, Nishio M, Hirata A, Kashiwase K, Ogasawara N, Hirotani S, Kodama K. Atherosclerotic and thrombogenic neointima formed over sirolimus drug-eluting stent: an angioscopic study. JACC Cardiovasc Imaging 2009;2:616-624.
46. Kang SJ, Mintz GS, Park DW, Lee SW, Kim YH, Lee CW, Han KH, Kim JJ, Park SW, Park SJ. Tissue characterization of in-stent neointima using intravascular ultrasound radiofrequency data analysis. Am J Cardiol 2010;106:1561-1565.
47. Takano M, Yamamoto M, Inami S, Murakami D, Ohba T, Seino Y, Mizuno K. Appearance of lipid-laden intima and neovascularization after implantation of bare-metal stents extended late-phase observation by intracoronary optical coherence tomography. J Am Coll Cardiol 2009;55:26-32.
48. Habara M, Terashima M, Nasu K, Kaneda H, Inoue K, Ito T, Kamikawa S, Kurita T, Tanaka N, Kimura M, Kinoshita Y, Tsuchikane E, Matsuo H, Ueno K, Katoh O, Suzuki T. Difference of tissue characteristics between early and very late restenosis lesions after bare-metal stent implantation: an optical coherence tomography study. Circ Cardiovasc Interv 2011;4:232-238.
49. Kang SJ, Mintz GS, Akasaka T, Park DW, Lee JY, Kim WJ, Lee SW, Kim YH, Whan Lee C, Park SW, Park SJ. Optical coherence tomographic analysis of in-stent neoatherosclerosis after drug-eluting stent implantation. Circulation 2011;123:2954-2963.
50. Yonetsu T, Kato K, Kim SJ, Xing L, Jia H, McNulty I, Lee H, Zhang S, Uemura S, Jang Y, Kang SJ, Park SJ, Lee S, Yu B, Kakuta T, Jang IK. Predictors for neoatherosclerosis: a retrospective observational study from the optical coherence tomography registry. Circ Cardiovasc Imaging 2012;5:660-666.
51. Nakano M, Vorpahl M, Otsuka F, Taniwaki M, Yazdani SK, Finn AV, Ladich ER, Kolodgie FD, Virmani R. Ex vivo assessment of vascular response to coronary stents by optical frequency domain imaging. JACC Cardiovasc Imaging 2012;5:71-82.
52. Otsuka F, Joner M, Prati F, Virmani R, Narula J. Clinical classification of plaque morphology in coronary disease. Nat Rev Cardiol 2014;11:379-389.
53. van Soest G, Regar E, Goderie TP, Gonzalo N, Koljenovic S, van Leenders GJ, Serruys PW, van der Steen AF. Pitfalls in plaque characterization by OCT: image artifacts in native coronary arteries. JACC Cardiovasc Imaging 2011;4:810-813.
54. Liang S, Saidi A, Jing J, Liu G, Li J, Zhang J, Sun C, Narula J, Chen Z. Intravascular atherosclerotic imaging with combined fluorescence and optical coherence tomography probe based on a double-clad fiber combiner. J Biomed Opt 2012;17:070501.
55. Vinegoni C, Botnaru I, Aikawa E, Calfon MA, Iwamoto Y, Folco EJ, Ntziachristos V, Weissleder R, Libby P, Jaffer FA. Indocyanine green enables near-infrared fluorescence imaging of lipid-rich, inflamed atherosclerotic plaques. Sci Transl Med 2011;3:84ra45.